Unplanned admissions to two Sydney public hospitals after naltrexone implants

Medical Journal of Australia

Volumn 188, Issue 8, 2008, Pages 441-444

  Lintzeris, Nicholas ^a   Lee, Soung ^a   Scopelliti, Lucinda ^a   Mabbutt, James ^a   Haber, Paul S ^a,b  

^a SYDNEY SOUTH WEST AREA HEALTH SERVICE   (Australia)

^b University of Sydney   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

NALTREXONE; NARCOTIC ANTAGONIST;

ANXIETY DISORDER; ARTICLE; AUSTRALIA; CLINICAL ARTICLE; DEHYDRATION; DETOXIFICATION; DEVICE INFECTION; DISEASE SEVERITY; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; DRUG WITHDRAWAL; HEART ARRHYTHMIA; HEROIN DEPENDENCE; HOSPITAL ADMISSION; HUMAN; INJECTION SITE ATROPHY; LENGTH OF STAY; PATIENT SELECTION; PUBLIC HOSPITAL; RETROSPECTIVE STUDY; SUICIDAL IDEATION; WITHDRAWAL SYNDROME; ADULT; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG IMPLANT; FEMALE; INCIDENCE; MALE; MULTICENTER STUDY; STATISTICS; TIME;

ADULT; DRUG IMPLANTS; FEMALE; HEROIN DEPENDENCE; HOSPITALS, PUBLIC; HUMANS; INCIDENCE; MALE; NALTREXONE; NARCOTIC ANTAGONISTS; NEW SOUTH WALES; PATIENT ADMISSION; RETROSPECTIVE STUDIES; SUBSTANCE WITHDRAWAL SYNDROME; TIME FACTORS;

EID: 47049106861     PISSN: 0025729X     EISSN: 13265377     Source Type: Journal    
DOI: 10.5694/j.1326-5377.2008.tb01712.x     Document Type: Article

References (18)

1. Adi Y, Juarez-Garcia A, Wang D, et al. Oral naltrexone as a treatment for relapse prevention in formerly opioid-dependent drug users: a systematic review and economic evaluation. Health Technol Assess 2007; 6: 1-85.
2. Garbutt JC, Kranzler HR, O'Malley SS, et al. Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial. JAMA 2005; 293: 1617-1625.
3. Johnson BA, Ait-Daoud N, Aubin HJ, et al. A pilot evaluation of the safety and tolerability of repeat dose administration of long-acting injectable naltrexone (Vivitrex) in patients with alcohol dependence. Alcohol Clin Exp Res 2004; 9: 1356-1361.
4. Swainston Harrison T, Plosker GL, Keam SJ. Extended-release intramuscular naltrexone. Drugs 2006; 66: 1741-1751.
5. Comer SD, Sullivan MA, Hulse GK. Sustained-release naltrexone: novel treatment for opioid dependence. Expert Opin Investig Drugs 2007; 8: 1285-1294.
6. Hulse GK, Arnold-Reed DE, O'Neil G, et al. Blood naltrexone and 6-beta-naltrexol levels following naltrexone implant: comparing two naltrexone implants. Addict Biol 2004; 9: 59-65.
7. Carreno JE, Alvarez CE, Narciso GI, et al. Maintenance treatment with depot opioid antagonists in subcutaneous implants: an alternative in the treatment of opioid dependence. Addict Biol 2003; 8: 429-438.
8. Colquhoun R, Tan DY, Hull S. A comparison of oral and implant naltrexone outcomes at 12 months. J Opioid Manag 2005; 1: 249-256.
9. Hulse GK, Tait RJ, Comer SD, et al. Reducing hospital presentations for opioid overdose in patients treated with sustained release naltrexone implants. Drug Alcohol Depend 2005; 79: 351-357.
10. Waal H, Frogopsahl G, Olsen L, et al. Naltrexone implants - duration, tolerability and clinical usefulness. A pilot study. Eur Addict Res 2006; 12: 138-144.
11. O'Neil G, Hulse G, Armstrong J, et al. Rapid opioid detoxification in Australia [comment]. Acad Emerg Med 2002; 9: 960.
12. Reece S. Rapid opioid detoxification in Australia [comment]. Acad Emerg Med 2002; 9: 960-962.
13. Therapeutic Goods Administration. Special access scheme at a glance. Canberra: Department of Health and Ageing, 2007. http://www.tga.gov.au/ hp/sasglance.htm (accessed Dec 2007).
14. Gibson AE, Degenhardt LJ, Hall WD. Opioid overdose deaths can occur in patients with naltrexone implants. Med J Aust 2007; 186: 152-153.
15. Wodak A, Graham R. Naltrexone implants as treatment for heroin dependence: part II [letter]. Addict Biol 2005; 10: 202.
16. Hamilton RJ, Olmedo RE, Shah S, et al. Complications of ultrarapid opioid detoxification with subcutaneous naltrexone pellets. Acad Emerg Med 2002; 9: 63-68.
17. Mehta A, Jain AC, Mehta MC. Electrocardiographic effects of intravenous cocaine: an experimental study in a canine model. J Cardiovasc Pharmacol 2003; 41: 25-30.
18. O'Brien B, Cody C. Analgesia and sedation in the presence of a naltrexone implant: a novel pharmacological challenge. Eur J Emerg Med 2006; 13: 315-316.